Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

For: Watanabe R, Hashimoto M. Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases. Ann Rheum Dis 2020;81:e262. [PMID: 32769155 DOI: 10.1136/annrheumdis-2020-217995] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 05/15/2020] [Indexed: 11/04/2022]

For:	Watanabe R, Hashimoto M. Elucidation of disease mechanisms underlying rheumatic immune-related adverse events may lead to novel therapeutic strategies for autoimmune diseases. Ann Rheum Dis 2020;81:e262. [PMID: 32769155 DOI: 10.1136/annrheumdis-2020-217995] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2020] [Accepted: 05/15/2020] [Indexed: 11/04/2022]

Number	Cited by Other Article(s)
1	Veccia A, Kostine M, Tison A, Dipasquale M, Kinspergher S, Prokop L, Grandi G, Inchiostro S, Caffo O, Paolazzi G, Bortolotti R, Cornec D, Berti A. Rheumatic immune- and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: a systematic review and meta-analysis. Joint Bone Spine 2022;89:105403. [DOI: 10.1016/j.jbspin.2022.105403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Revised: 03/25/2022] [Accepted: 03/30/2022] [Indexed: 11/28/2022] Abstract Collapse Key Words Collapse MESH Headings Collapse Grants Collapse Affiliation(s) Collapse

Number

Cited by Other Article(s)

Veccia A, Kostine M, Tison A, Dipasquale M, Kinspergher S, Prokop L, Grandi G, Inchiostro S, Caffo O, Paolazzi G, Bortolotti R, Cornec D, Berti A. Rheumatic immune- and nonimmune-related adverse events in phase 3 clinical trials assessing PD-(L)1 checkpoint inhibitors for lung cancer: a systematic review and meta-analysis. Joint Bone Spine 2022;89:105403. [DOI: 10.1016/j.jbspin.2022.105403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Revised: 03/25/2022] [Accepted: 03/30/2022] [Indexed: 11/28/2022]